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Abstract: We previously demonstrated that interleukin (IL)-7/15 was superior to IL-2 for 
expansion of T cells in vitro for adoptive immunotherapy. We sought to ascertain whether 
IL-21 would further improve yield and therapeutic efficacy of T cells in culture. Naïve T cell 
receptor (TcR) transgenic splenocytes or antigen-sensitized lymph node cells were harvested 
from PMEL-1 mice and exposed to bryostatin-1 and ionomycin (B/I) for 18 h. Cells were 
then cultured in IL-2, IL-21, IL-7/15 or IL-7/15/21 for six days. Harvested cells were 
analyzed by flow cytometry and used to treat C57Bl/6 mice injected intravenously with  
B16 melanoma. Lungs were harvested and metastases counted 14 days after treatment.  
Culturing lymphocytes in IL-7/15/21 increased expansion compared to IL-2 or IL-7/15. IL-21 
and IL-7/15/21 increased CD8+ cells compared to IL-2 or IL-7/15. IL-21 preferentially 
expanded a CD8+CD44−CD62L+ T “naïve” population, whereas IL-7/15/21 increased 
CD8+CD44+CD62Lhigh central-memory T cells. T cells grown in IL-7/15/21 were more 
effective at reducing metastases than IL-2. The addition of IL-21 to IL-7/15 induced greater 
expansion of lymphocytes in culture and increased the yield of CD8+ T central-memory cells 
vs. IL-7/15 alone. This may have significant impact on future clinical trials of adoptive 
immunotherapy, particularly for generating adequate numbers of lymphocytes for treatment. 
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1. Introduction 
Adoptive immunotherapy (AIT), the infusion of ex vivo expanded lymphocytes, has been extensively 
studied in animals and humans [1–5]. Although this therapy has demonstrated promising results in 
multiple murine tumor models, a regimen that optimizes both lymphocyte expansion as well as tumor 
regression for human therapy remains elusive. AIT takes advantage of ex vivo activation and expansion 
of T cells away from the suppressive in vivo tumor environment and allows for “re-programming” of the 
immune cells to optimize their functional status. It also allows for additional treatment of the host  
(e.g., host lymphocyte depletion) prior to the re-introduction of the selected cells, which may decrease 
immunosuppression, and optimize trafficking and/or proliferation of the infused cells. 
We have shown that T cells from both naïve splenocytes and tumor antigen-sensitized draining lymph 
nodes (DLN) could be expanded with exposure to interleukins (IL)-7 and 15 after activation with 
bryostatin and ionomycin (B/I) to significantly greater numbers than the current standard approach using 
IL-2 alone [6]. These T cells were also able to cure melanoma metastases as effectively as, and 
sometimes better than, T cells grown in IL-2 [6]. Bryostatin-1 is a macrocyclic lactone derived  
from Bulgula neritina, a marine invertebrate. In culture, bryostatin activates protein kinase C, while 
ionomycin increases intracellular calcium [7–9]. When combined, these mimic signaling through the 
CD3/TcR complex and promote activation and proliferation of T cells [6,10–16]. B/I selectively 
activates CD62L- T cells, which represent the “sensitized” T cells capable of anti-tumor activity and is 
unique to B/I activation compared to anti-CD3 activation [7,15]. These T cells are similar to CAR T 
cells in the sense that all their CD8 T cells carry a transgenic T cell receptor that recognizes a single 
epitope present on B16 melanoma cells. We have also shown that this method of stimulation, combined 
with alternate cytokines, re-programs human T cells and NK cells, making them resistant to suppression 
by myeloid derived suppressor cells [10]. Phenotypically, whereas IL-2 expansion has been shown to 
lead to the induction of regulatory T cells and cause T cell activation induced cell death, IL-7/15 has 
been shown by this lab and others to support preferential differentiation of CD8+ T cells towards a 
central memory (TCM) phenotype [6,14,17]. This central memory phenotype has been suggested in 
multiple studies to be more effective at inducing tumor regression than terminally differentiated effector 
cells, which are more likely to be selectively expanded when T cells are grown in IL-2 [17,18]. Although 
using IL-2 to stimulate the proliferation of anti-tumor T cells in culture remains the standard clinical 
approach, we were encouraged by our results with IL-7/15 to add or substitute IL-21 to our expansion 
regimen. IL-21 is the most recently identified member of the family of cytokines that share the common 
gamma chain cytokine receptor with IL-2, IL-7 and IL-15 [19,20]. Preliminary experiments performed 
by other groups demonstrated that IL-21 has potent immunomodulatory effects on T cells as well as  
NK cells [21–24]. Both IL-15 and IL-21 have been shown in multiple experiments to enhance the  
in vivo anti-tumor effects of CD8+ T cells and in some cases to potentiate tumor regression [24–30]. 
Because of the promising results seen with IL-21 to date, we endeavored to discover whether B/I  
and IL-21 exposure alone or in combination with IL-7/15 would increase the expansion of naïve or 
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antigen-sensitized T cells, and whether it would increase anti-tumor activity. In addition, the T cell 
phenotype stimulated by exposure to IL-21 has varied in studies over the last decade, with some 
demonstrating increase in TCM cells while others claimed inhibition of this phenotype [19,31,32]. 
Therefore, we also performed flow cytometry analysis of cells expanded in different cytokines to 
elucidate which phenotypes were preferentially selected for after exposure to bryostatin, ionomycin and 
various cytokines. 
2. Results and Discussion 
2.1. Comparative Analysis of T Cell Expansion 
In repeated experiments, expansion of cells from naïve splenocytes in the IL-7/15 and IL-7/15/21 
groups was dramatically higher than for either IL-2 or IL-21. Whereas expansion in IL-2 ranged from  
1- to 2.8-fold increase on day 6, cells grown in IL-7/15 expanded from 8.9- to 24.2-fold and in IL-7/15/21 
cell numbers increased 9.2- to 37.2-fold. Averaged over five experiments, fold expansion was 1.9 for  
IL-2, 2.2 for IL-21, 15.0 for IL-7/15 and 23.8 for IL-7/15/21. Fold increases in expansion for IL-7/15 
and IL-7/15/21 were significantly higher than for either IL-2 or IL-21 (all p < 0.0006). However, fold 
increase for IL-7/15 and IL-7/15/21 were not significantly different from each other (p = 0.51). DLN 
lymphocyte expansion demonstrated similar results. Over three experiments IL-7/15/21 consistently had 
the highest expansion of cell numbers ranging from 13.3 to 38.5-fold expansion compared with IL-7/15 
(7.6- to 26.4-fold), IL-21 (0.9- to 3.3-fold) and IL-2 (3.7-fold). Again, expansion in IL-7/15 and  
IL-7/15/21 were significantly greater than in IL-2 or IL-21 (all p < 0.0039), but not significantly different 
from each other. However, there was a trend in favor of IL-7/15/21 expansion (p = 0.13). It is important 
to note that when cells were cultured for a total of 14 days, lymphocytes grown in IL-2 not only stopped 
expanding, but also rapidly began to die and therefore could not be included in expansion data, flow 
cytometry analysis, or treatment groups. 
2.2. Comparison of T Cell Phenotype with Various Cytokine Exposure 
At day 6 of expansion, splenocytes and DLN lymphocytes were analyzed by flow cytometry. Cells 
were stained for CD4, CD8, CD62L and CD44 simultaneously with appropriate nil controls as well as 
single color and isotype controls. In all cases, they were analyzed on the same day or within 24 h of 
staining and fixing. In four of four repeated experiments with splenocytes, IL-21 and IL-7/15/21 
expanded the highest percentage of CD8+ T-cells on day 6 compared to IL-2 or IL-7/15 (Figure 1a,b). 
The average CD8+ percentages for splenocytes on day 6 of expansion were 52.7% for IL-21 and 59.6% 
for IL-7/15/21, compared to 20.8% on day 0 after B/I pulse (p < 0.01, p < 0.01), 26.2% for day 6 in  
IL-2 (p < 0.06, p < 0.04) and 29.8% for IL-7/15 (p < 0.05, p < 0.03). CD8+ lymphocyte yield from DLN 
was significantly higher for day 6 IL-7/15/21 compared to day 0 (p = 0.0304) (Figure 1c). Taking 
phenotypic proportions and total cell yields into account, splenocytes exposed to IL-7/15/21 produced 
1456.8 million CD8+ T cells on day 6 vs. 487.9 million (p = 0.0044) for cells grown in IL-7/15,  
191.9 million (p < 0.0001) for cells grown in IL-21, and 97.7 million (p < 0.0001) for cells grown in  
IL-2 (Figure 2). Tumor-sensitized DLN cells demonstrated a similar trend at day 6, but the differences 
were not as dramatic nor were they significantly different from one another: 497.3, 214.7, 53.5 and  
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39.5 million CD8+ cells for IL-7/15/21, IL-7/15, IL-21 and IL-2 respectively, from a starting number of  
9.2 million cells on average for each group. 
(a) 
(b) 
 
(c) 
 
Figure 1. On day 0 before activation with bryostatin-1 and ionomycin (B/I) and six days 
after B/I activation and culture in IL-2, IL-21, IL-7/15 or IL-7/15/21, splenocytes were 
stained for CD4 and CD8 and analyzed by flow cytometry (a); Cells were FSC/SSC gated 
on viable lymphocytes and percentages of CD4 and CD8 (numbers in black) were 
determined. Average percentages of CD8+ T cells from splenocytes in five experiments,  
* (vs. day 0) = p < 0.01, † (vs. IL2) = p < 0.04, ‡ (vs. IL7/15) = p < 0.05 (b) and DLN 
lymphocytes in three experiments, * (vs. day 0) = p = 0.03 (c) expanded before and after 
exposure to B/I and six days of IL-2, IL-21, IL-7/15 or IL-7/15/21. 
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Figure 2. The percentages of CD8+ splenocytes were multiplied by the number of total cells 
expanded to obtain actual yield of cells in that subset, * (vs. day 0) = p < 0.0001, † (vs. IL2) 
= p < 0.0001, ‡ (vs. IL21) = p < 0.0001, • (vs. IL7/15) = p < 0.004. 
Flow cytometry analysis was also performed for CD8+ T cell subsets for both splenocytes and DLN 
lymphocytes on day 0 and after 6 days of expansion (Figure 3a). Splenocytes grown in IL-7/15/21 
consistently expanded or sustained a higher percentage of CD8+ T central memory (TCM) cells vs. all 
other groups (Figure 3b). Whereas the average percentage of CD8+ TCM cells harvested after 6 days in 
IL-2 (7.3%), IL-21 (5.4%) or IL-7/15 (10.3%) were not significantly different from one another, the 
proportion was significantly increased with expansion in IL-7/15/21 (23.6%) compared to IL-2  
(p = 0.0424) and IL-21 (p < 0.003) and trended towards significance compared to IL-7/15 (p = 0.056). 
DLN lymphocytes demonstrated a similar pattern, with IL-7/15/21 sustaining or expanding a population 
of CD8+ cells of which 43.1% were TCM cells vs. 23.2% for IL-7/15, 30.5% for IL-21 and 18.1% for  
IL-2 at day 6 vs. 15.0% at day 0, but these differences were not statistically significant. An interesting 
finding that correlates with observations noted in previously published studies was that IL-21 alone 
sustained or preferentially expanded a CD8+CD62L+CD44− population of T cells, a population 
designated classically as “T naive” (“TN”) (Figure 3c) [25,31]. Splenocytes expanded for 6 days in  
IL-21 alone yielded 38.6% with this “TN” phenotype compared to IL-2 (2.6%, p = 0.0014), IL-7/15 
(11.6%, p < 0.029), IL-7/15/21 (22.9%, p = 0.155) and day 0 (3.4%, p < 0.016). When the total  
number of cells expanded was taken into account, there were marked differences among the groups.  
For splenocytes, culture in IL-7/15/21 yielded an average of 625.7 million CD8+ TCM cells by day 6 
compared to IL-2, IL-21 and IL-7/15 [41.7 (p < 0.01), 15.8 (p = 0.0004) and 159 million cells (p = 0.125), 
respectively at day 6] (Figure 4a). DLN lymphocytes also responded similarly, with total CD8+ TCM 
cells grown in IL-7/15/21 at 350 million on day 6 compared to IL-2 (27.2 million), IL-21 (31.1 million) 
and IL-7/15 (106.8 million) (none significant due to the limited sample size). Although the percentages 
of “TN” cells were highest with IL-21 alone, because of the greater overall expansion of T cells in the 
IL-7/15/21 group, that group demonstrated the highest total number of expanded “TN” cells, with  
628 million cells at day 6 for the splenocyte group compared to 134 million cells for IL-21 (p = 0.09) at 
day 6, and 186 million cells for IL-7/15 (p = 0.15) (Figure 4b). DLN lymphocytes expanded with  
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IL-7/15/21 resulted in an actual yield of 16.9 million “TN” cells, which was significantly higher than  
IL-2 expanded “TN” cells at 0.3 million (p < 0.03). 
(a) 
(b) 
 
(c) 
 
Figure 3. On day 0 and six days after B/I activation and culture in IL-2, IL-21, IL-7/15 or 
IL-7/15/21, splenocytes were stained for CD4, CD8, CD44 and CD62L and analyzed by 
flow cytometry to determine the percentages of T cell subsets: CD44+CD62L− T effector 
(TE), CD44+CD62Llow T effector memory (TEM), CD44+CD62Lhigh T central memory 
(TCM) and CD44−CD62L+ “T naïve” (“TN”) cells (a); Cells were FSC/SSC gated on viable 
lymphocytes and CD8+ T cells and percentages of T cell subsets (in black) were determined. 
Results are from a representative experiment out of five independent experiments with 
similar results. Average percentage of TCM, † (vs. IL2) = p = 0.04, ‡ (vs. IL21) = p < 0.003,  
• (vs. IL7/15) = p = 0.056 (b) or TN, * (vs. day 0) = p < 0.016, † (vs. IL2) = p = 0.0014,  
‡ (vs. IL7/15) = p < 0.029 (c) for cells expanded from splenocytes in five experiments before 
and after B/I activation and culture for six days in IL-2, IL-21, IL-7/15 or IL-7/15/21. 
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(a) 
 
(b) 
 
Figure 4. The percentages of CD8+ TCM, † (vs. IL2) = p < 0.01, ‡ (vs. IL21) = p = 0.004 (a) 
and CD8+ TN (b) splenocytes were multiplied by the number of total cells expanded to obtain 
actual yield of cells in that subset. 
2.3. IFN-Gamma Release ELISA 
When B/I pulsed and IL-7/15/21 exposed splenocyte T cells were co-cultured with B16 cells for  
24 h, the amount of IFN-γ release was significantly higher than in those splenocyte T cells exposed to 
IL-2 and co-cultured with B16 cells, averaged over three experiments (p = 0.04) (Figure 5). T cells 
exposed to IL-7/15 and co-cultured with B16 cells approached significance compared to IL-2 exposed 
T cells cultured with B16 cells (p = 0.06), a finding we had demonstrated previously [6]. The amount of 
IFN-γ produced by IL-7/15 exposed and IL-7/15/21 exposed T cells co-cultured with B16 cells were not 
significantly different from each other (p = 0.85). Two controls were utilized, a control tumor, LLC, was 
used to demonstrate that the IFN-γ release from the T cells was specific to exposure to B16, and the 
cytokine exposed T cells alone, without tumor co-culture. Only the IL-7/15 and the IL-7/15/21 exposed 
T cells when co-cultured with B16 were significantly different from their LLC and alone controls  
(p < 0.05), whereas the IL-2 and IL-21 exposed T cells when co-cultured with B16 were not significantly 
different from their controls (p = 0.24–0.99). 
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Figure 5. Interferon-gamma ELISA assay. B/I pulsed and IL-2, IL-21, IL-7/15 and  
IL-7/15/21 exposed spleen-derived T cells were co-cultured with B16 melanoma cells, Lewis 
lung carcinoma (LLC) cells or media alone for 24 h. The amount of IFN-γ release was 
significantly higher in the group exposed to IL-7/15/21 and approached significance in the 
group exposed to IL-7/15 than for spleen-derived T cells expanded in IL-2 or IL-21 and  
co-cultured with B16 cells, † (vs. IL2+B16) 9 = p < 0.04 (IL-7/15/21), p = 0.06 (IL-7/15). 
2.4. Treatment of B16 Melanoma Metastases with Lymphocytes Exposed to Different Cytokines 
Compared to the control group, mice treated with cyclophosphamide alone or cyclophosphamide  
plus AIT with the standard dose of spleen-derived lymphocytes (10 million cells/mouse) expanded for 
7 days in IL-2, IL-7/15 or IL-7/15/21 exhibited significantly fewer metastatic lung nodules (Figure 6a)  
(p = 0.0369, p = 0.0330, p < 0.0001, p < 0.0001). At this dose of cells, IL-7/15 and IL-7/15/21 expanded 
cells were significantly better at curing metastases than cyclophosphamide alone (p < 0.0001,  
p < 0.0001), whereas IL-2 expanded cells were not more effective than CYP alone (p = 0.49). However, 
only the IL-7/15/21 expanded cells were significantly better than cyclophosphamide alone for curing 
metastases at a lower dose of T cells (2 million cells per mouse) (p = 0.002). In addition, when compared 
to AIT with 10 million cells grown in IL-2 (the current standard), IL-7/15 and IL-7/15/21 expanded cells 
were significantly better at curing metastases at the same cell dose (10 million) (p < 0.0002, p < 0.0007), 
with the majority sustaining complete cures (zero metastases seen). In our experiments, we found that 
AIT with cells expanded in IL-21 alone, whether at 10 million or 2 million cells, was not statistically 
significantly different from the control or CYP groups (p = 0.27, p = 0.59). A similar experiment was 
performed with DLN-derived lymphocytes (Figure 6b). Both IL-7/15 and IL-7/15/21 expanded 
lymphocytes were significantly better than control at the lower dose of AIT (two million cells) at curing 
melanoma metastases (p = 0.002, p = 0.004). However, at the standard dose of ten million cells both 
IL7/15 an IL7/15/21 expanded cells were capable of curing metastases significantly better than control, 
CYP only, and both groups at the two million cell dose (p < 0.02). 
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(b) 
 
Figure 6. Average number of metastases in untreated mice, mice treated with 
cyclophosphamide (CYP) only and mice treated with cyclophosphamide and adoptive 
immunotherapy (AIT) with doses of either 10 million or 2 million spleen-derived T cells (a) 
activated with B/I and cultured for seven days in IL-2, IL-21, IL-7/15 or IL-7/15/21, * (vs. 
control) = p < 0.037, † (vs. CYP) = p < 0.0001, ‡ (CYP vs. IL7/15/21 2 million) = p = 0.002, 
• (vs. IL2 10 million) = p < 0.0007, and DLN derived T cells (b) activated with B/I and 
cultured for seven days in IL-7/15 or IL-7/15/21, * (vs. control) = p < 0.0019, † (vs. CYP) = 
p < 0.0002, ‡ (vs. IL7/15 2 million) = p < 0.02, • (vs. IL7/15/21 2 million) = p < 0.005. 
3. Discussion 
These results demonstrate that culturing splenocytes and DLN lymphocytes for AIT with IL-7/15/21 
results in a much higher yield of cells with equal or greater activity against melanoma metastases than 
those cultured in either IL-2 (the current standard cytokine for expansion) or even the combination of 
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IL-7+15. Many studies to date have demonstrated that therapy with exogenous IL-21 or with 
lymphocytes exposed to IL-21 alone are superior to various combinations of cytokines [24,29,32–34]. 
Others have shown an improved effect of IL-21 combined with IL-2, IL-15 or IL-7 alone [2,22,25,31,35], 
However, to our knowledge this is the first study examining the effect of IL-7, -15 and -21 concurrently 
on in vitro lymphocyte expansion. Klebanoff et al. [1] recently reviewed which factors were associated 
with the most effective adoptive immunotherapy. Of the factors examined, absolute number of infused 
cells was strongly correlated with the magnitude of tumor regression. They also found that the least 
differentiated cells demonstrated the most robust anti-tumor activity. In their experience, both T central 
memory (TCM) cells and T memory stem cells (TSCM) led to significant delay in tumor growth compared 
to untreated controls or mice receiving T effector memory (TEM) cells. They found that TSCM cells  
caused a more sustained reduction in tumor growth compared to TCM cells. They also found that no 
single gamma chain cytokine, when administered exogenously, was significantly better at augmenting  
anti-tumor function than any other single cytokine. They go on to suggest that it is difficult to uncouple 
the process of cell expansion and differentiation status in that the longer the cells are expanded ex vivo, 
the more differentiated they become, and therefore, using longer durations of in vitro expansion to 
increase total cell numbers sacrifices more effective TCM cells in favor of less effective terminally 
differentiated TE cells. However, our results demonstrate that expanding splenocytes in IL-7/15/21 after 
activation with B/I results in a dramatic increase in the total numbers of cells, with the actual yield of 
CD8+ T cells capable of numbering over one billion after only 6 days of expansion from an average 
starting cell number of 30 million. Of these CD8+ T cells, over half were shown to be TCM cells  
(~625 million). Splenocytes expanded in IL-7/15/21 were then subsequently found to cure metastases  
in vivo without vaccine or exogenous cytokine administration, even at low doses of cells. This finding 
demonstrates that even with longer times in culture and prolific expansion, lymphocytes grown in  
IL-7/15/21 are capable of achieving high numbers of total cells, the majority of which are TCM cells that 
have a significant anti-tumor effect in vivo. In addition, this also demonstrates that the TCM cells needn’t 
be sorted to a pure population for effective anti-tumor function. However, if desired, the total number of 
TCM cells produced by expansion with IL-7/15/21 is such that a significant number could be enriched for 
therapeutic use. However, not requiring a sorted population renders adoptive immunotherapy more 
clinically feasible. 
We consistently observed that splenocytes expanded in IL-2 or IL-21 alone did not expand well, were 
not effective at curing B16 metastases compared to controls, and did not produce IFN-γ when exposed 
to B16 tumor cells to a significantly different level compared to controls. These IL-2 and IL-21 exposed 
splenocytes, perhaps unsurprisingly, were the least efficacious at curing or slowing tumor growth. 
Overall, we found that the IL-7/15/21 cultured splenocytes had the greatest expansion, produced the 
greatest percentage of CD8+ T cells, the greatest number of CD8+ TCM cells, had the highest amount of 
IFN-γ production when co-cultured with B16 cells and were most efficacious at curing metastases  
in vivo. The actual yield of CD8+ T cells and CD8+ TCM cells was significantly higher in IL-7/15/21 
cultured splenocytes compared to IL-7/15 splenocytes, which we had previously shown to be superior 
to IL-2 cultured T cells [6]. 
In multiple papers, it has been suggested that exposure to IL-21 alone causes lymphocytes to remain in 
or differentiate into a minimally differentiated phenotype (CD62L+CD44−), and that these lymphocytes 
have greater anti-tumor capacity relative to cells expanded in other gamma chain cytokines [25,34,36]. 
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Gattinoni et al. [37] describe lymphocytes expanded in IL-21 alone, demonstrating a CD62L+CD44− 
phenotype described as TSCM-like cells. They explain that because of the unique ability of IL-21 among 
gamma chain cytokines to sustain STAT3 activation, this maintains a “TSCM-like state that is associated 
with high proliferative potential and long-term T cell survival” [37]. Unfortunately, in our experiments, 
although lymphocytes expanded in IL-21 indeed were enriched for the CD62L+CD44− phenotype, this 
did not translate into either higher proliferative capacity in vitro nor greater anti-tumor efficacy in vivo. 
This may be because our method of activation with B/I does not support development of TSCM-like cells 
after exposure to IL-21, or because TSCM-like cells produced by exposure to IL-21 in culture are not as 
effective as has been demonstrated in earlier studies. 
4. Experimental Section 
4.1. Mice 
Virus-free C57Bl/6 mice (National Cancer Institute, National Institutes of Health, Bethesda, MD, 
USA) between 8 and 12 weeks of age, caged in groups of 6 or fewer, were provided with food and water 
ad libitum. T cell receptor (TcR) transgenic PMEL-1 mice, with T cell receptors (TcR) specific for the 
peptide KVPRNQDWL, from the shared melanocyte/melanoma differentiation antigen gp100, were 
produced from breeding pairs obtained from Jackson Laboratories (Bar Harbor, Maine). All guidelines 
of the Virginia Commonwealth University Institutional Animal Care and Use Committee, which 
conform to the American Association for Accreditation of Laboratory Animal Care and the U.S. 
Department of Agriculture recommendations for the care and humane experimental use of animals,  
were followed. 
4.2. Tumor Cell Lines 
B16-GMCSF and B16-F10 tumor cell lines were kindly provided by Richard Dutton (Trudeau 
Institute, Saranac Lake, NY, USA) and by Rodney Prell (Cell Genesys, Inc., South San Francisco, CA, 
USA), respectively. Melanoma cells were cultured in complete RPMI 1640 with 10% heat-inactivated 
fetal calf serum, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids, 0.075% sodium bicarbonate,  
2 mM L-glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin, 10 mM Hepes buffer, and 5 × 10−5 M  
2-mercaptoethanol (Sigma, St. Louis, MO, USA). All cells were incubated in 250 mL T-flasks  
(PGC, Gaithersburg, MD, USA) at 37 °C in humidified air with 5% CO2. Tumor cells were harvested 
from culture with 0.05% trypsin-EDTA (Invitrogen, Grand Island, NY, USA) washed twice with  
1× PBS and re-suspended in 1× PBS for inoculation of mice. 
4.3. Draining Lymph Node Sensitization 
PMEL-1 mice were inoculated in one hind footpad with 5 × 105 B16-GMCSF cells. Ten days  
after footpad vaccination, popliteal tumor draining lymph nodes (DLN) were harvested under  
sterile conditions. 
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4.4. Lymphocyte Activation and in Vitro Expansion 
Draining lymph nodes (DLNs) or spleens were harvested and dispersed into single cell suspensions in 
complete RPMI media at 1 × 106 cells/mL. Splenic mononuclear cells were enriched by Lympholyte-M 
density gradient centrifugation and residual erythrocytes were removed by suspension in ammonium 
chloride potassium (ACK). These cells were then activated by incubation with 5 nM bryostatin-1 
(provided by the National Cancer Institute, Bethesda, MD, USA) and 1 μM ionomycin (Calbiochem, 
San Diego, CA, USA) (B/I) and 80 U/mL of rIL-2 (Chiron, Emeryville, VA, USA) at 37 °C for 18 h. 
Cells were washed three times with warm complete RPMI and re-suspended at 1–2 × 106 cells/mL with 
either 40 U/mL of rIL-2, 5 ng/mL of IL-21 (BD Biosciences, San Jose, CA, USA), 5 ng/mL each of  
IL-7 (BD Biosciences, San Jose, CA, USA) and IL-15 (BD Biosciences, San Jose, CA, USA), or  
5 ng/mL each of IL-7, IL-15 and IL-21. The cells were allowed to proliferate in culture for an additional 
6–7 days and were split every 2–3 days in order to maintain 1× 106–2 × 106 cells/mL concentration and 
additional cytokine was added at 40 U/mL or 5 ng/mL with each split. 
4.4. Adoptive Immunotherapy 
For B16 melanoma lung metastases, mice were inoculated with 250,000 B16 melanoma cells 
intravenously (IV) 4 days prior to AIT. Mice were pretreated on the day prior to AIT with 100 mg/kg of 
intraperitoneal (IP) cyclophosphamide (CYP, Mead Johnson, Princeton, NJ, USA). AIT consisted of  
IV infusion of lymphocytes from cultures at either 2 or 10 million cells/mouse harvested 7 days after 
activation in vitro. No systemic cytokines or vaccines were administered to the recipient mice. In all AIT 
experiments, mice were euthanized by CO2 inhalation 14 days after tumor cell infusion and lungs were 
removed, fixed in 10% formaldehyde, and melanoma lung nodules were counted under a dissecting 
microscope, as previously described [38]. 
4.5. Flow Cytometry 
T cells isolated from DLN and spleens were stained with a panel of antibodies on day 0 (immediately 
after B/I activation) and on day 6 after activation in vitro. These stained cells were analyzed by multicolor 
flow cytometry for surface markers on a FACSAria Canto flow cytometer. Fluorescently labeled 
antibodies directed against the following markers were obtained from Biolegend and eBiosciences: CD4, 
CD8, CD62L, and CD44. Appropriate isotype controls were used in all cases. T cell subsets analyzed 
were T effector (TE) CD44+CD62L−, T effector memory (TEM) CD44+CD62Llow, T central memory 
(TCM) CD44+CD62Lhigh and “T naïve” (“TN”) CD44–CD62L+, as described in earlier studies and 
reviews [39–41]. 
4.6. IFN-γ ELISA 
Splenocytes were cultured with B/I and cytokines for 7 days as described above. The cells were then 
harvested, washed and cultured in complete medium at a ratio of 10:1 with irradiated B16 tumor cells  
or Lewis lung carcinoma (LLC) irradiated cells, as a control, for 24 h. Splenocytes alone, tumor cells 
alone and media alone were also cultured concurrently as controls. Supernatants were then collected and 
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stored at −80 °C until assay. IFN-γ was detected using a Mouse IFN-γ ELISA kit (BD Pharmingen,  
San Jose, CA, USA) according to the manufacturer’s protocol and performed in duplicate. 
4.7. Statistical Analysis 
At least five mice were included in each experiment. Each outcome was summarized with basic 
descriptive statistics such as mean and standard deviation for each cytokine. Repeated measures analysis 
of variance through a linear mixed model was used to compare the various cytokine conditions in fold 
increase cell numbers on day 6 from baseline, in each T cell phenotype (including both percentage and 
total number of cells of CD4 and CD8, and TE, TEM, TCM, and TN), in number of lung melanoma 
metastases, and in ELISA. Pairwise comparisons of the various cytokines were made and tested at type 
I error of 5% by a t-test with the random measurement errors estimated by the linear mixed model. 
Normality was checked for each analysis. Natural logarithm was used in the data of fold increase of  
T cell expansion, ELISA, and percentage and total numbers of T cell phenotypes, and square root was 
used in number of lung melanoma metastases for normality. SAS 9.2 was used for all analyses. 
5. Conclusions 
In conclusion, we demonstrate here that lymphocytes expanded in the triple combination of  
IL-7/15/21 have a large proliferative capacity, significantly greater than the current standard of IL-2 
expansion, and are capable of producing billions of CD8+ T cells and hundreds of millions of CD8+ 
TCM cells from a starting population of only tens of millions of lymphocytes total. These IL-7/15/21 
expanded lymphocytes are capable of inducing regression of metastatic B16 melanoma, even at low 
doses of cells. In addition, these effects are seen when the total expanded lymphocyte population is 
utilized for therapy, without the need for sorting a specific phenotypic subset of T-cells and without 
utilizing exogenous cytokine or vaccinations in vivo. These results show great promise for producing 
large numbers of effective anti-tumor T cells for future human trials. Also, although demonstrating 
similar phenotypic characteristics to TSCM-like cells, we found that lymphocyte expansion in IL-21alone 
improved neither their ability to proliferate in vitro nor their ability to cause tumor regression in vivo.  
It is therefore unclear whether the CD62L+CD44− IL-21 expanded lymphocytes are indeed TSCM-like cells. 
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